HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Analysis of the response and toxicity to gefitinib of non-small cell lung cancer

Files in This Item:
AR25-1B.pdf252.73 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/15889

Title: Analysis of the response and toxicity to gefitinib of non-small cell lung cancer
Authors: Konishi, Jun Browse this author
Yamazaki, Koichi Browse this author
Kinoshita, Ichiro Browse this author
Isobe, Hiroshi Browse this author
Ogura, Shigeaki Browse this author
Sekine, Satoko Browse this author
Ishida, Takashi Browse this author
Takashima, Rioh Browse this author
Nakadate, Megumi Browse this author
Nishikawa, Syu Browse this author
Hattori, Takeshi Browse this author
Asahina, Hajime Browse this author
Imura, Mikado Browse this author
Kikuchi, Eiki Browse this author
Kikuchi, Junko Browse this author
Shinagawa, Naofumi Browse this author
Yokouchi, Hiroshi Browse this author
Munakata, Mituru Browse this author
Dosaka-Akita, Hirotoshi Browse this author
Nishimura, Masaharu Browse this author
Keywords: Response
Toxicity
Non-small cell lung cancer
Gefitinib
Issue Date: 2005
Publisher: International Institute of Anticancer Research
Journal Title: Anticancer Research
Volume: 25
Issue: 1B
Start Page: 435
End Page: 441
PMID: 15816608
Abstract: Background: Gefitinib is an oral agent that inhibits the tyrosine kinase of epidermal growth factor receptor (EGFR), which had antitumor activity in patients with previously treated non-small cell lung cancer (NSCLC). We analyzed the efficacy, toxicitiy, and overall survival time of gefitinib in patients with NSCLC. Patients and Methods: One hundred and twenty-two patients with NSCLC who received gefitinib between 2002 and 2004 in our institutes were evaluated retrospectively. Results: The objective response rate was 24.6%. The variables identified as significant in univariate analysis included gender and smoking habit. The median overall survival time was 14.4 months. Significant variables associated with improved survival included good performance status (PS), female, adenocarcinoma and never smoked status, and never smoked status and good PS were independent prognostic factors in multivariate analysis. Four patients (3.3%) developed interstitial pneumonitis associated with gefitinib. Conclusion: Gefitinib showed favorable anti-tumor activity in females, never smokers and adenocarcinoma.
Type: article (author version)
URI: http://hdl.handle.net/2115/15889
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 山崎 浩一

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

 - Hokkaido University